Susanne K.
- Country
- Germany
- Department
- #40529: Klinik und Poliklinik für Neurologie
Research Overview
- Efficacy and Safety of Vormatrigine in Adults with Focal Epilepsy Receiving Concomitant Antiseizure Medications: A Randomized, Double-Blind, Placebo-Controlled Trial
- The ENACT Trial: A Randomized, double-blind, placebo-controlled adjunctive treatment trial to evaluate the efficacy and safety of ENX-101 in patients with focal (partial onset) seizures
- A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)
Data & Insights
Has run more than one trial at 135 of 208 partner sites.
Specializations
Focal Epilepsy Research
This investigator specializes in studying therapeutic approaches for focal onset seizures, with particular emphasis on refractory focal epilepsy. Their research encompasses evaluating novel therapeutic compounds for patients whose seizures are not adequately controlled by standard treatments.
- Focal onset seizures
- Drug-resistant epilepsy
- Adjunctive therapy approaches
Generalized Seizure Management
The investigator conducts research in primary generalized tonic-clonic seizures and idiopathic generalized epilepsy. Their work involves evaluating therapeutic interventions for various forms of generalized seizures.
- Generalized tonic-clonic seizures
- Idiopathic generalized epilepsy
- Long-term seizure management
Emergency Seizure Care
Research focuses on acute interventions for status epilepticus, including specialized treatment approaches for elderly patients and management of prolonged seizure episodes. The investigator studies rapid-acting therapeutic options for emergency seizure control.
- Refractory status epilepticus
- Acute seizure intervention
- Emergency seizure management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.